Topic: Mylan

Mylan CEO Heather Bresch faced intense questioning from a House Oversight Committee regarding the 400% price increase of life-saving EpiPens. Representative Scott DesJarlais and other lawmakers excoriated Bresch for profiting from a monopoly while the company's wholesale acquisition cost reached $608. Bresch defended the company by citing the introduction of a $300 generic version and programs to provide free devices to schools.

The pharmaceutical company Mylan faced congressional scrutiny after raising the price of EpiPens from $100 to over $600. The hosts characterize the price hike as part of a larger "insurance scam" facilitated by the Affordable Care Act, where drug companies inflate costs while the FDA prevents generic competition from entering the market.